Preventing Crohn's Disease recurrence after resection with adalimumab: Role of drug and anti-drug antibody levels

被引：0
|
作者：
Wright, E. [1 ,2 ]
Kamm, M. [1 ,2 ,3 ]
Selvaraj, F. [4 ]
Princen, F. [4 ]
De Cruz, P. [1 ,2 ]
Hamilton, A. [1 ,2 ]
Ritchie, K. [1 ,2 ]
Krejany, E. [1 ,2 ]
Gorelik, A. [1 ,2 ]
Liew, D. [1 ,2 ]
Prideaux, L. [1 ,2 ]
Lawrance, I. [1 ,2 ]
Andrews, J. [1 ,2 ]
Bampton, P. [1 ,2 ]
Jakobovits, S. [1 ,2 ]
Florin, T. [1 ,2 ]
Gibson, P. [1 ,2 ]
Debinski, H. [1 ,2 ]
Gearry, R. [1 ,2 ]
Macrae, F. [1 ,2 ]
Samuel, D. [1 ,2 ]
Kronborg, I. [1 ,2 ]
Radford-Smith, G. [1 ,2 ]
Selby, W. [1 ,2 ]
Johnston, M. [1 ,2 ]
Woods, R. [1 ,2 ]
Elliott, P. R. [1 ,2 ]
Bell, S. [1 ,2 ]
Brown, S. [1 ,2 ]
Connell, W. [1 ,2 ]
Desmond, P. [1 ,2 ]
Singh, S. [4 ]
机构：
[1] St Vincents Hosp, Melbourne, Vic, Australia
[2] Univ Melbourne, Gastroenterol, Melbourne, Vic, Australia
[3] Univ London Imperial Coll Sci Technol & Med, Med, London, England
[4] Prometheus Labs, Dept Res & Dev, San Diego, CA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2015年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P585
引用
收藏
页码：S373 / S373
页数：1
相关论文
共 50 条
  • [21] Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels
    Ruiz-Argueello, Begona
    del Agua, Ainhoa Ruiz
    Torres, Nerea
    Monasterio, Alberto
    Martinez, Antonio
    Nagore, Daniel
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2013, 51 (12) : E287 - E289
  • [22] HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease
    Sazonovs, Aleksejs
    Kennedy, Nicholas A.
    Moutsianas, Loukas
    Heap, Graham A.
    Rice, Daniel L.
    Reppell, Mark
    Bewshea, Claire M.
    Chanchlani, Neil
    Walker, Gareth J.
    Perry, Mandy H.
    McDonald, Timothy J.
    Lees, Charlie W.
    Cummings, J. R. Fraser
    Parkes, Miles
    Mansfield, John C.
    Irving, Peter M.
    Barrett, Jeffrey C.
    McGovern, Dermot
    Goodhand, James R.
    Anderson, Carl A.
    Ahmad, Tariq
    GASTROENTEROLOGY, 2020, 158 (01) : 189 - 199
  • [23] EVALUATION OF MARKETED KITS FOR MEASUREMENT OF ABP 501, THE FIRST APPROVED ADALIMUMAB BIOSIMILAR, DRUG CONCENTRATION AND ANTI-DRUG ANTIBODY LEVELS IN PATIENT SERUM
    Mytych, Dan
    Manning, Marta Starcevic
    Colbert, Alexander
    Hoofring, Sarah
    Miller, Jill
    Gessner, Melissa
    Chow, Vincent
    Fanjiang, Gary
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1020 - 1020
  • [24] Anti-TNF and Anti-Drug Antibodies Levels Predict the Outcomes of Interventions After Loss of Response to Adalimumab and Infliximab
    Yanai, Henit
    Lichtenstein, Lev
    Assa, Amit
    Mazor, Yoav
    Weiss, Batia
    Levine, Arie
    Ron, Yulia
    Kopylov, Uri
    Bujanover, Yoram
    Rosenbach, Yoram
    Ungar, Bella
    Eliakim, Abraham R.
    Chowers, Yehuda
    Shamir, Raanan
    Fraser, Gerald
    Dotan, Iris
    Ben-Horin, Shomron
    GASTROENTEROLOGY, 2014, 146 (05) : S381 - S381
  • [25] Intrapatient Variability in Adalimumab Drug Levels Within and Across Cycles in Crohn's disease
    Ward, Mark G.
    Beswick, Lauren
    Thwaites, Phoebe
    Hogg, Julie
    Rosella, Gennaro
    Reynolds, John
    van Langenberg, Daniel R.
    Gibson, Peter R.
    Sparrow, Miles
    GASTROENTEROLOGY, 2016, 150 (04) : S414 - S414
  • [26] Higher Adalimumab Drug Levels Are Associated with Mucosal Healing in Patients with Crohn's Disease
    Papamichael, Konstantinos
    Cheifetz, Adam S.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (05): : 507 - 509
  • [27] Adalimumab: Relevance of drug trough levels and antibodies assessment in the prognosis of Crohn's disease
    Perdigoto, D.
    Macedo, C.
    Portela, F.
    Lopes, S.
    Ferreira, M.
    Mendes, S.
    Ferreira, M.
    Tome, L.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S377 - S378
  • [28] Intrapatient variability in adalimumab drug levels within and across cycles in Crohn's disease
    Ward, M.
    Beswick, L.
    Thwaites, P.
    Hogg, J.
    Rosella, G.
    Reynolds, J.
    Van Langenberg, D.
    Gibson, P.
    Sparrow, M.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S346 - S347
  • [29] Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with inflammatory bowel disease
    Strik, A.
    van den Brink, G.
    Ponsioen, C.
    Mathot, R.
    Lowenberg, M.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S69 - S70
  • [30] METHOD COMPARISON STUDY OF ASSAYS FOR THE DETERMINATION OF INFLIXIMAB, ADALIMUMAB, AND ANTI-DRUG ANTIBODY LEVELS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES
    Nagore, D.
    Ruiz del Agua, A.
    Pascual, J.
    Llinares-Tello, F.
    Herreros, B.
    Martinez, A.
    Martin, S.
    Navarro, R.
    del Rio, L.
    GUT, 2015, 64 : A99 - A100
12345